For many people with ulcerative colitis, diet feels like a daily puzzle: some foods settle things, others stir them up, and it is not always clear why. Part of the answer may lie not in the food itself, but in what happens to it after it reaches the colon, where trillions of bacteria break it down into substances that can directly influence gut inflammation. One such substance, butyrate, has become a focus of research into how diet and the microbiome might support the gut lining during ulcerative colitis.
What is butyrate?
Butyrate is a short-chain fatty acid produced when gut bacteria ferment fibre that escapes digestion in the small intestine. It forms mainly in the colon, where bacterial groups break down resistant starches and soluble fibres from foods such as oats, beans, and cooked and cooled potatoes. Butyrate is barely absorbed into the bloodstream; instead it is used largely on the spot by the cells lining the colon, which rely on it as their preferred energy source.
Why it matters for gut inflammation
The colon lining is a single layer of cells forming a barrier between gut bacteria and the rest of the body. In ulcerative colitis, this barrier becomes inflamed and more permeable, letting bacterial components and immune triggers through more easily and perpetuating inflammation. Butyrate matters here for two reasons: it fuels the cells maintaining this barrier, and it interacts directly with immune cells in the gut lining, helping regulate how aggressively the immune system responds. Since ulcerative colitis involves both a weakened barrier and an overactive immune response, a molecule supporting both sides has naturally drawn research interest.
Key mechanisms
Fuelling the gut lining
Colonocytes use butyrate as their main energy source, more so than glucose. With adequate butyrate supply, these cells can repair minor damage and keep the tight junctions between cells functioning properly. Studies have observed reduced butyrate-producing bacteria in ulcerative colitis, which some researchers propose may leave colon cells relatively starved of their preferred fuel and less resilient, though this relationship is still being clarified.
Calming immune signalling
Butyrate can influence regulatory T cells, which help keep inflammation in check rather than letting it escalate unchecked. Laboratory research suggests it may encourage development of these cells and dampen pro-inflammatory signalling pathways. This doesn’t mean butyrate switches off the immune system, but it may help tilt the balance away from the persistent, low-grade activation seen in ulcerative colitis.
Supporting the mucus layer
The colon’s protective mucus layer keeps most bacteria at a safe distance from the cell surface. Some research indicates butyrate may support the cells producing this mucus, helping maintain its thickness and quality. A thinner or disrupted mucus layer has been observed in ulcerative colitis, and strengthening it is one way butyrate might contribute to barrier resilience.
The microbiome connection
Butyrate production depends on specific bacterial species, including some from the Firmicutes group, having enough suitable fibre to ferment. A narrower range of bacteria, commonly reported in ulcerative colitis, may mean lower overall butyrate output even with reasonable fibre intake. This is why researchers favour dietary approaches supporting a broader, more butyrate-producing bacterial community, rather than targeting a single food or supplement.
Flares versus remission
Fibre fermentation and gas production can sometimes cause bloating or discomfort, particularly during active flares when the gut is already sensitive. The relationship between fibre, butyrate, and symptoms is therefore not always straightforward, and tolerance can differ between flare and remission. Symptoms during a flare do not necessarily mean butyrate production is at fault, and easing off certain fibres temporarily is sometimes appropriate under professional guidance.
Butyrate research is promising, but it is not a treatment in itself, and no supplement or diet currently replaces prescribed medical therapy for ulcerative colitis. Symptoms can also arise from causes other than active inflammation, such as altered gut motility or sensitivity, so changes in how someone feels should not automatically be read as disease activity without proper assessment.
Practical takeaways
- Introduce fibre-rich foods gradually, particularly when moving from a flare into remission.
- Include varied fibre sources, such as oats, legumes, and cooked and cooled starchy foods, rather than relying on one type.
- Discuss significant dietary changes, including fibre increases or supplements, with a gastroenterologist or dietitian familiar with your history.
- Track patterns over weeks rather than days, since microbiome and symptom changes unfold gradually.
- Continue prescribed treatment as directed, even if dietary changes seem to help, unless a clinician advises otherwise.
Conclusion
Butyrate offers a useful window into how diet, the microbiome, and gut inflammation connect in ulcerative colitis, even though it is not a cure or standalone treatment. The evidence points to a biologically plausible role for butyrate in supporting the gut lining and moderating immune activity, but individual responses vary, and more clinical research is needed before firm dietary recommendations can be made for all patients. Long-term stability in ulcerative colitis likely comes from a consistent, well-tolerated diet combined with appropriate medical care, rather than any single nutrient or food. Working with a gastroenterologist or dietitian remains the most reliable way to tailor these principles safely to individual circumstances.
References
- Roediger WE. Role of anaerobic bacteria in the metabolic welfare of the colonic mucosa in man. Gut. 1980;21(9):793-798. doi:10.1136/gut.21.9.793
- Furusawa Y, Obata Y, Fukuda S, et al. Commensal microbe-derived butyrate induces the differentiation of colonic regulatory T cells. Nature. 2013;504(7480):446-450. doi:10.1038/nature12721
- Vernia P, Marcheggiano A, Caprilli R, et al. Short-chain fatty acid topical treatment in distal ulcerative colitis. Aliment Pharmacol Ther. 1995;9(3):309-313. doi:10.1111/j.1365-2036.1995.tb00386.x
- Machiels K, Joossens M, Sabino J, et al. A decrease of the butyrate-producing species Roseburia hominis and Faecalibacterium prausnitzii defines dysbiosis in patients with ulcerative colitis. Gut. 2014;63(8):1275-1283. doi:10.1136/gutjnl-2013-304833
- Scheppach W. Treatment of distal ulcerative colitis with short-chain fatty acid enemas. Dig Dis Sci. 1996;41(11):2254-2259. doi:10.1007/BF02071409
- Hamer HM, Jonkers D, Venema K, et al. Review article: the role of butyrate on colonic function. Aliment Pharmacol Ther. 2008;27(2):104-119. doi:10.1111/j.1365-2036.2007.03562.x
- Sun M, Wu W, Liu Z, Cong Y. Microbiota metabolite short chain fatty acids, GPCR, and inflammatory bowel diseases. J Gastroenterol. 2017;52(1):1-8. doi:10.1007/s00535-016-1242-9
This article is intended for informational and educational purposes only. It does not constitute medical advice and should not be used as a substitute for professional medical guidance, diagnosis, or treatment.